← Tiziana Life Sciences Ltd (TLSA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Tiziana Life Sciences Ltd (TLSA)
Pharmaceutical Preparations · market cap $116M · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31
Phase 2
Pipeline
4
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Tiziana Life Sciences (TLSA) is a micro-cap pharmaceutical company with 9 employees and a ~$146M market cap trading at ~$1.23. Its lead asset is Foralumab Nasal, a nasal formulation in Phase 2 for Multiple System Atrophy (MSA), with additional Phase 2 programs in Secondary Progressive Multiple Sclerosis (SPMS) and a separate Phase 2 oncology asset (Milciclib) in Hepatocellular Carcinoma. Key binary readouts are expected through mid-2027.
The catalyst path
- 2026-10-31Phase 2 · Foralumab Nasalimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Foralumab Nasal | Phase 2 | Multiple System Atrophy |
| Foralumab | Phase 2 | Secondary Progressive Multiple Sclerosis |
| Foralumab TZLS-401 100 µg | Phase 2 | Non-Active Secondary Progressive Multiple Sclerosis |
| Milciclib maleate | Phase 2 | Hepatocellular Carcinoma |
Price & technical context
3-month
-9.8%
6-month
-5.1%
12-month
-47.9%
52-wk range
$0.77–$2.29
vs 50-day MA
+11.2%
vs 200-day MA
-12.4%
Realized vol
80.3%
Max drawdown
-69.2%
Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for TLSA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 4 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.